Vor Biopharma Inc.
Datakwaliteit: 83%
VOR
Nasdaq
Manufacturing
Chemicals
€ 15,52
▼
€ 0,23
(-1,43%)
Marktkapitalisatie: 758,11 M
Prijs
€ 15,52
Marktkapitalisatie
758,11 M
Dagbereik
€ 15,50 — € 16,39
52-Weeksbereik
€ 2,62 — € 65,80
Volume
617.795
Openen € 15,60
50D / 200D Gem.
€ 14,26
8,82% above
50D / 200D Gem.
€ 23,90
35,07% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -143,65 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-193,16%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio9,16
Interest CoverageN/A
Waardering
PE (TTM)
-1,09
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -695,98 M |
| ROE | N/A | ROA | -364,76% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -143,65 M |
| ROIC | -193,16% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 9,16 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 153,65 M | Tangible Book Value | -2,23 B |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,09 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -18,95% | ||
| Market Cap | 758,11 M | Enterprise Value | 597,65 M |
| Per Share | |||
| EPS (Diluted TTM) | -70,50 | Revenue / Share | N/A |
| FCF / Share | -2,94 | OCF / Share | -2,92 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 20,64% |
| SBC-Adj. FCF | -157,72 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -695,98 M | -116,91 M | -117,86 M | -92,09 M | -68,90 M |
| EPS (Diluted) | -70,50 | -1,70 | -1,75 | -2,33 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -371,64 M | -121,19 M | -126,04 M | -93,42 M | -69,02 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 321,53 M | 93,31 M | 94,32 M | 64,55 M | 47,53 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 464,13 M | 142,89 M | 198,13 M | 299,37 M | 242,59 M |
| Total Liabilities | 628,44 M | 46,23 M | 47,40 M | 48,76 M | 26,33 M |
| Shareholders' Equity | -164,31 M | 96,66 M | 150,72 M | 250,61 M | 216,26 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 396,49 M | 81,95 M | 31,36 M | 57,71 M | 119,80 M |
| Current Assets | 458,11 M | 96,51 M | 140,80 M | 236,95 M | 214,40 M |
| Current Liabilities | 25,17 M | 18,61 M | 15,57 M | 13,12 M | 10,15 M |
{"event":"ticker_viewed","properties":{"ticker":"VOR","listing_kind":"stock","pathname":"/stocks/vor","exchange":"Nasdaq","country":"US"}}